首页> 外文期刊>Liver international >Assessing Baveno VI criteria with liver stiffness measured using a new point-shear wave elastography technique (BAVElastPQ study)
【24h】

Assessing Baveno VI criteria with liver stiffness measured using a new point-shear wave elastography technique (BAVElastPQ study)

机译:使用新的点横波弹性成像技术评估肝脏硬度的 Baveno VI 标准(BAVElastPQ 研究)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and Aims To date, no study has explored the potential role of ElastPQ, a novel point-SWE technique, in the assessment of clinically significant portal hypertension. The aim of our study was to determine a liver stiffness (LS) cut-off value measured by ElastPQ and laboratory parameters that could help to identify those patients who can safely avoid screening endoscopy. Methods Data were collected on 1422 patients who underwent ElastPQ measurement from January 2013 to January 2016 in our Department. Inclusion criteria were a LS value of >= 7 kPa, an upper gastrointestinal endoscopy within 12 months and a diagnosis of compensated chronic liver disease. Exclusion criteria were history of decompensated liver disease, evidence of porto-spleno-mesenteric vein thrombosis and non-cirrhotic portal hypertension. Varices were graded as low-risk varices (grade = 2). Results The study included 195 patients (120 61 HCV, 171 88 Child-Pugh A). Varices were present in 35 cases, with 10 prevalence of VNT. According to ROC curve analysis, LS measurement and platelet count were evaluated as predictors of VNT. Overall, 75/195 (38) met the 'BAVElastPQ' criteria (that is, LS 150 000/mu L). Within this group, 11/75 (15) had any grade of varices and only 1/75 (1) had VNT. The BAVElastPQ criteria gave sensitivity of 0.95, specificity of 0.42, positive predictive value of 0.15 and negative predictive value of 0.99. Conclusions The BAVElastPQ criteria correctly identified 99 of patients without VNT. By applying such criteria, we could have potentially avoided 38 of surveillance endoscopies in our cohort.
机译:背景和目的 迄今为止,尚无研究探讨 ElastPQ(一种新型点 SWE 技术)在评估具有临床意义的门静脉高压症方面的潜在作用。我们研究的目的是确定通过 ElastPQ 测量的肝脏硬度 (LS) 临界值和实验室参数,以帮助识别那些可以安全避免筛查内窥镜检查的患者。方法 收集2013年1月至2016年1月在我科行ElastPQ检测的1422例患者资料。纳入标准是 LS 值为 >= 7 kPa,12 个月内进行过上消化道内镜检查,诊断为代偿性慢性肝病。排除标准是失代偿性肝病史、门-脾-肠系膜静脉血栓形成和非肝硬化门静脉高压症的证据。静脉曲张被分级为低风险静脉曲张(等级 = 2)。结果 该研究纳入195例患者(120例[61%]HCV,171例[88%]Child-Pugh A)。静脉曲张见于 35% 的病例,VNT 的患病率为 10%。根据ROC曲线分析,LS测量和血小板计数作为VNT的预测因子。总体而言,75/195 (38%) 符合“BAVElastPQ”标准(即 LS 150 000/亩升)。在该组中,11/75 (15%) 有任何级别的静脉曲张,只有 1/75 (1%) 有 VNT。BAVElastPQ 标准给出的敏感性为 0.95,特异性为 0.42,阳性预测值为 0.15,阴性预测值为 0.99。结论 BAVElastPQ标准正确识别了99%的无VNT患者。通过应用这些标准,我们本可以避免我们队列中 38% 的监测内窥镜检查。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号